Skip to main content
. 2019 Aug 13;10(8):610. doi: 10.1038/s41419-019-1826-4

Fig. 7. Verapamil rescued HCM phenotype in MLP-deficient CMs.

Fig. 7

a Representative line-scan images in WT (blue), MLP KO (red), and MLP KO hESC-CMs treated with 100 nM verapamil (green) for 10 continuous days beginning at day 20 of cardiac differentiation (n = 13). b–d Quantification of peak, time to peak, and calcium transient duration in WT, MLP KO, and verapamil-treated MLP KO hESC-CMs (n = 12). e, f Forward scatter (FSC) and g, h Mitotracker green intensity obtained by flow cytometry in WT, MLP KO, and verapamil-treated MLP KO hESC-CMs. i Heatmap representations of hypertrophy related gene expression in WT, MLP KO, and verapamil-treated MLP KO hESC-CMs. j, k Immunoblot analysis of P-CaMKII and quantification of P-CAMKII normalized by GAPDH in WT, MLP KO, and verapamil-treated MLP KO hESC-CMs (n = 3). Results are presented as means ± S.E.M. of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant, unpaired two-sided Student’s t test